A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

PURPOSE: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors. PATIENTS AND METHODS: A 3+3 dose escalation design was used. During dose escalation, CT900 doses of 1–6 mg/m(2) weekly and 2–...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Susana, Michalarea, Vasiliki, Ang, Joo Ern, Ingles Garces, Alvaro, Biondo, Andrea, Funingana, Ionut-Gabriel, Little, Martin, Ruddle, Ruth, Raynaud, Florence, Riisnaes, Ruth, Gurel, Bora, Chua, Sue, Tunariu, Nina, Porter, Joanna C., Prout, Toby, Parmar, Mona, Zachariou, Anna, Turner, Alison, Jenkins, Ben, McIntosh, Stuart, Ainscow, Ed, Minchom, Anna, Lopez, Juanita, de Bono, Johann, Jones, Robert, Hall, Emma, Cook, Natalie, Basu, Bristi, Banerji, Udai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623233/
https://www.ncbi.nlm.nih.gov/pubmed/35984704
http://dx.doi.org/10.1158/1078-0432.CCR-22-1268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623233/
https://www.ncbi.nlm.nih.gov/pubmed/35984704
http://dx.doi.org/10.1158/1078-0432.CCR-22-1268

Ejemplares similares